Summit’s Ivonescimab Delivers First Major PFS Win in EGFR-Mutated Lung Cancer After TKI Failure

HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.